JP2010518122A - 間質性肺疾患および喘息のためのトレプロスチニル処置 - Google Patents

間質性肺疾患および喘息のためのトレプロスチニル処置 Download PDF

Info

Publication number
JP2010518122A
JP2010518122A JP2009549268A JP2009549268A JP2010518122A JP 2010518122 A JP2010518122 A JP 2010518122A JP 2009549268 A JP2009549268 A JP 2009549268A JP 2009549268 A JP2009549268 A JP 2009549268A JP 2010518122 A JP2010518122 A JP 2010518122A
Authority
JP
Japan
Prior art keywords
treprostinil
pulmonary fibrosis
pharmaceutically acceptable
kit
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009549268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518122A5 (https=
Inventor
ウェイド，マイケル
リッチ，スチュワート
サリバン，ユージン
ロシーニョ，ロバート
ジェフス，ロジャー
Original Assignee
ユナイテッド セラピューティクス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユナイテッド セラピューティクス コーポレーション filed Critical ユナイテッド セラピューティクス コーポレーション
Publication of JP2010518122A publication Critical patent/JP2010518122A/ja
Publication of JP2010518122A5 publication Critical patent/JP2010518122A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
JP2009549268A 2007-02-09 2008-02-08 間質性肺疾患および喘息のためのトレプロスチニル処置 Withdrawn JP2010518122A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90032007P 2007-02-09 2007-02-09
US94021807P 2007-05-25 2007-05-25
PCT/US2008/053467 WO2008098196A1 (en) 2007-02-09 2008-02-08 Treprostinil treatment for interstitial lung disease and asthma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013116923A Division JP2013189459A (ja) 2007-02-09 2013-06-03 間質性肺疾患および喘息のためのトレプロスチニル処置

Publications (2)

Publication Number Publication Date
JP2010518122A true JP2010518122A (ja) 2010-05-27
JP2010518122A5 JP2010518122A5 (https=) 2011-03-10

Family

ID=39357950

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009549268A Withdrawn JP2010518122A (ja) 2007-02-09 2008-02-08 間質性肺疾患および喘息のためのトレプロスチニル処置
JP2013116923A Pending JP2013189459A (ja) 2007-02-09 2013-06-03 間質性肺疾患および喘息のためのトレプロスチニル処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013116923A Pending JP2013189459A (ja) 2007-02-09 2013-06-03 間質性肺疾患および喘息のためのトレプロスチニル処置

Country Status (7)

Country Link
US (4) US20080280986A1 (https=)
EP (2) EP2120961A1 (https=)
JP (2) JP2010518122A (https=)
KR (1) KR20090117781A (https=)
CN (2) CN102648916A (https=)
CA (1) CA2678258A1 (https=)
WO (1) WO2008098196A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505082A (ja) * 2011-02-07 2014-02-27 サイファーム ソシエテ ア レスポンサビリテ リミテ 嚢胞性線維症の処置のための新規組成物
KR20140070545A (ko) * 2011-08-12 2014-06-10 아센디스 파마 에이에스 담체-연결된 트레프로스티닐 전구약물
JP2014522878A (ja) * 2011-08-12 2014-09-08 アセンディス ファーマ エー／エス プロスタサイクリンの徐放組成物
JP2023523557A (ja) * 2020-04-17 2023-06-06 ユナイテッド セラピューティクス コーポレイション 間質性肺疾患の治療における使用のためのトレプロスチニル

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2622471T5 (es) * 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
WO2005099680A2 (en) * 2004-04-12 2005-10-27 United Therapeutics, Inc. Use of treprostinil to treat neuropathic diabetic foot ulcers
US20070023047A1 (en) * 2005-07-26 2007-02-01 Moshe Zalsman Face mask particularly useful as medical face mask
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
EP2026816B1 (en) 2006-05-15 2018-10-24 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
CN101903324B (zh) 2007-12-17 2013-07-03 联合治疗公司 一种制备Remodulin中的活性成分曲前列素的改良方法
CA2723540C (en) * 2008-05-08 2016-01-05 United Therapeutics Corporation Treprostinil monohydrate
US8349892B2 (en) * 2009-05-07 2013-01-08 United Therapeutics Corporation Solid formulations of prostacyclin analogs
RS53234B (sr) 2009-08-07 2014-08-29 Scipharm Sàrl Kompozicija za lečenje cistične fibroze
ES2611187T3 (es) * 2010-03-15 2017-05-05 United Therapeutics Corporation Tratamiento para hipertensión pulmonar
JP6046034B2 (ja) 2010-06-03 2016-12-14 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの製造
US20120010159A1 (en) * 2010-07-09 2012-01-12 United Therapeutics Corporation Combination therapies with cox-2 inhibitors and treprostinil
WO2012107364A1 (en) * 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
US20130345471A1 (en) 2011-03-02 2013-12-26 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
EP2913047B1 (en) * 2012-10-29 2019-05-08 Cardio Incorporated Pulmonary disease-specific therapeutic agent
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
JP2016517410A (ja) 2013-03-14 2016-06-16 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの固体形態
CN109608326A (zh) 2013-03-15 2019-04-12 联合治疗公司 曲前列环素的盐
JP6263604B2 (ja) 2013-03-25 2018-01-17 ユナイテッド セラピューティクス コーポレイション チオールリンカーを持つ、ペグ化型のプロスタサイクリン化合物の製造方法
ES2860975T3 (es) 2013-10-25 2021-10-05 Insmed Inc Compuestos de prostaciclina
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
US20170088897A1 (en) * 2014-06-03 2017-03-30 Novartis Ag Pulmonary hypertension biomarker
ES2908142T3 (es) * 2014-06-13 2022-04-27 United Therapeutics Corp Formulaciones de treprostinil
US9593061B2 (en) 2014-10-20 2017-03-14 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
CA2967899C (en) 2014-12-03 2023-09-19 Steadymed Ltd Preservative-free treprostinil formulations and methods and devices for use with same
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
JP7220650B2 (ja) 2016-09-26 2023-02-10 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
CN108379557A (zh) * 2018-01-15 2018-08-10 吉林大学 使用白介素因子-37治疗特发性肺纤维化
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
JP7449275B2 (ja) 2018-05-02 2024-03-13 インスメッド インコーポレイテッド リポソーム薬物製剤の製造方法
ES2976468T3 (es) 2018-09-18 2024-08-01 Lilly Co Eli Sal de treprostinil erbumina
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
EP4017588A1 (en) 2019-08-23 2022-06-29 United Therapeutics Corporation Treprostinil prodrugs
IL298591A (en) 2020-06-09 2023-01-01 United Therapeutics Corp Pomeryl dictopiperidine prodrugs of treprostinil
IL303431A (en) * 2020-12-07 2023-08-01 Mannkind Corp Method and composition for the treatment of pulmonary fibrosis
KR20250133451A (ko) 2020-12-14 2025-09-05 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법
JP2024510930A (ja) 2021-03-03 2024-03-12 ユナイテッド セラピューティクス コーポレイション トレプロスチニル及びそのプロドラッグの乾燥粉末組成物、及び、さらに（ｅ）－３，６－ビス［４－（ｎ－カルボニル－２－プロペニル）アミドブチル］－２，５－ジケトピペラジン（ｆｄｋｐ）を含む乾燥粉末組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005225877A (ja) * 1997-11-14 2005-08-25 United Therapeutics Corp 末梢血管疾患治療のための９−デオキシ−２’，９−α−メタノ−３−オキサ−４，５，６−トリノール−３，７−（１’，３’−インターフェニレン）−１３，１４−ジヒドロ−プロスタグランジンＦ１の使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
GB8814438D0 (en) * 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
KR0158870B1 (ko) * 1988-06-17 1998-12-01 마틴 에이. 로쓰블랫 폐순환 승압의 치료, 예방 또는 진단용 조성물
US6441245B1 (en) * 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
WO2000055314A2 (en) * 1999-03-18 2000-09-21 United Therapeutics Corporation Inhibitors of endothelin-1 synthesis
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6756047B2 (en) * 2000-05-12 2004-06-29 The University Of Toledo Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
ES2622471T5 (es) * 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
EP2026816B1 (en) * 2006-05-15 2018-10-24 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005225877A (ja) * 1997-11-14 2005-08-25 United Therapeutics Corp 末梢血管疾患治療のための９−デオキシ−２’，９−α−メタノ−３−オキサ−４，５，６−トリノール−３，７−（１’，３’−インターフェニレン）−１３，１４−ジヒドロ−プロスタグランジンＦ１の使用

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505082A (ja) * 2011-02-07 2014-02-27 サイファーム ソシエテ ア レスポンサビリテ リミテ 嚢胞性線維症の処置のための新規組成物
US9504663B2 (en) 2011-02-07 2016-11-29 Scipharm Sarl Composition for the treatment of cystic fibrosis
KR20140070545A (ko) * 2011-08-12 2014-06-10 아센디스 파마 에이에스 담체-연결된 트레프로스티닐 전구약물
JP2014522878A (ja) * 2011-08-12 2014-09-08 アセンディス ファーマ エー／エス プロスタサイクリンの徐放組成物
JP2014527050A (ja) * 2011-08-12 2014-10-09 アセンディス ファーマ エー／エス 担体連結しているトレプロスチニルプロドラッグ
KR101997939B1 (ko) * 2011-08-12 2019-07-08 아센디스 파마 에이에스 담체-연결된 트레프로스티닐 전구약물
JP2023523557A (ja) * 2020-04-17 2023-06-06 ユナイテッド セラピューティクス コーポレイション 間質性肺疾患の治療における使用のためのトレプロスチニル

Also Published As

Publication number Publication date
CA2678258A1 (en) 2008-08-14
EP2491932A2 (en) 2012-08-29
CN102648916A (zh) 2012-08-29
KR20090117781A (ko) 2009-11-12
US20140018431A1 (en) 2014-01-16
US20130096200A1 (en) 2013-04-18
US20080280986A1 (en) 2008-11-13
WO2008098196A1 (en) 2008-08-14
EP2491932A3 (en) 2012-12-12
CN101678033A (zh) 2010-03-24
EP2120961A1 (en) 2009-11-25
JP2013189459A (ja) 2013-09-26
US20120129941A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
JP2010518122A (ja) 間質性肺疾患および喘息のためのトレプロスチニル処置
ES2331187T3 (es) Utilizacion de treprostinil para mejorar las funciones renales.
JP6761929B2 (ja) Ｆｇｆ１９の新規な治療用途
JP5795165B2 (ja) 慢性虚血における亜硝酸塩の使用
US20190160150A1 (en) Acth for treatment of acute respiratory distress syndrome
US20250236676A1 (en) TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODY
Chon et al. Effects of long-term iloprost treatment on right ventricular function in patients with Eisenmenger syndrome
JP2003535892A (ja) ２−アラキドニルグリセロール（２−ＡＧ）−腫瘍壊死因子−αの阻害剤および閉鎖性頭部損傷における脳の神経保護因子
Komori et al. Blockade of OSMRβ signaling ameliorates skin lesions in a mouse model of human atopic dermatitis
KR20230011929A (ko) 간질성 폐 질환의 치료에 사용하기 위한 트레프로스티닐
JP2016106121A (ja) Ｔｈ３マーチ関連疾患の治療及び予防用医薬組成物
JP2011256145A (ja) Ｔｈ３マーチ関連疾患の治療及び予防用医薬組成物
EP4233851A1 (en) A soluble guanylat cyclase activator for treating chronic vascular dysfunction
CA2889826C (en) METHODS OF TREATING PULMONARY HYPERTENSION BY ADMINISTRATION OF A C-SIGNALLY NATRURETIC PEPTIDE RECEPTOR OF SEQUENCE ACTIVATORS
JP2025502098A (ja) うつ病の治療のための組成物及び方法
JP6594899B2 (ja) 特発性肺線維症の治療方法
US20040266880A1 (en) Antipruritics
US20250302804A1 (en) Resomelagon and its derivatives for the treatment of cardiovascular disease, hypertension and atherosclerosis
US20250387391A1 (en) A soluble guanylat cyclase activator for treating chronic vascular dysfunction
JP6429401B2 (ja) 変異を有するｉ型コラーゲンの小胞体内過剰蓄積正常化剤
US20240408112A1 (en) Method for preventing or treating pulmonary arterial hypertension by using 7-dehydrocholesterols or salts, oxides, metabolites, or derivatives thereof
US20260042816A1 (en) Tyrosine kinase inhibitor and activin type 2 receptor antagonist combination therapy for treating pulmonary arterial hypertension (pah)
WO2025037259A1 (en) Methods and compositions for preventing or treating severe asthma
TW202532439A (zh) 治療氣喘之方法
Karsentya et al. SESSION PL ENIERE: METABOLISMES, DU GENE AU PATIENT

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131030

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131112

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141015

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150202